PRLog (Press Release) - Jul 29, 2012 - MONMOUTH JUNCTION, NJ - Approximately 55% of proteins in the human body are glycosylated proteins. Proteins require separation from samples containing glycosylated and non glycosylated proteins. Glycoproteomics is the study of glycoproteins and analysis of glycoproteins by proteomic methods. Researchers are interested in the identification of biomarkers from samples containing glycoproteins to search and identify aberrant glycoproteins. Thus glycoproteomics integrates glycoprotein enrichment and proteomics technologies to find and quantify glycoproteins.
NuGel™ Glycoprotein Enrichment PBA product is ideal for mining glycoproteins and represents a new paradigm for biomarker discovery from glycoproteins. Providing unrivalled specificity, NuGel™ Glycoprotein Enrichment product contains phenyl boronic acid ligand(PBA) which covalently reacts with 1,2-cis-diol group containing molecules. The PBA ligand binds to the 1,2-cis-diol groups of biomolecules and enriches for heterogeneous sets of glycoproteins containing both N-linked and O-linked oligosaccharides. The specialized heterogenous nature of NuGel™ Glycoprotein Enrichment PBA product organo-boronic acid groups makes it applicable to all kinds of glycopeptides regardless of the sizes, structures, and hydrophilicities. This complex can easily be displaced by suitable buffer containing sorbital. The eluted enriched glycoproteins are ideal for glycoprotein profiling from plasma, serum, bodily fluids, or tissues. This unique chemistry eliminates the requirement for forming complex saccharide recognition motifs for interaction. NuGel™ Glycoprotein Enrichment PBA Kit provides good reproducibility, simple protocol, and high-throughput capability. Biotech Support Group's NuGel™ Glycoprotein Enrichment PBA product is compatible with proteomics and analytical technology (multidimensional chromatographic separation and high-resolution mass spectrometry) for glycoproteins analysis. NuGel™ Glycoproteins Enrichment product is supplied both in a kit format and also in bulk. Glycoprotein isolation and enrichment might lead to biomarkers present in tissue extracts and physiological fluids.
NuGel™ Glycoproteins Enrichment PBA product is compatible with combinations of affinity-enrichment techniques, chemical and biochemical protocols, and advanced mass spectrometry to facilitate detailed glycoprotein analysis in proteomics, from fundamental biological studies for biomarker discovery. After using NuGel™ Glycoproteins Enrichment product, combining chemical tagging for isolation and isotope labeling for mass spectrometry analysis would allow researchers to develop highly effective strategies for glycoproteomics. Cancer biologists are interested in finding biomarkers for early correlations with diseases according to the protein's glycosylation state and comparison with disease states.
Characteristics of NuGel™ Glycoprotein Enrichment PBA Kit
• Cis-diol specific, enriches heterogeneous sets of glycoproteins
• Unmasks glycoproteins from high abundance proteins, most notably albumin
• Disposable, no column regeneration or cross-contamination
• Efficient new surface technology ideal for proteomic applications
• Enriches glycoproteins from blood, serum, plasma, tissue or cell culture media
• Sorbitol elution at pH 7.5 – 8.5
• Adaptable to liquid chromatography (LC) and high-throughput 96-well format
About Biotech Support Group LLC
Biotech Support Group LLC is a leading provider of genomics and proteomics sample preparation products and enrichment reagent kits as well as integrated biotechnology services for life sciences research, biomarker and drug discovery. Based in New Jersey, it’s principal products include: AlbuVoid™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, NuGel™ for passivated silica-based affinity chromatography, and ProCipitate™ & ProPrep™ for nucleic acid isolation. Currently, Biotech Support Group LLC and ProFACT Proteomics Inc., are collaborating on the development of a proteomics platform used in functional profiling for proteomic analysis and a separations method for generating sub-proteomes used in biomarker and functional proteomic prospecting. For more information, go to www.biotechsupportgroup.com
Biotech Support Group
1 Deer Park Drive, Suite M,
Monmouth Junction, NJ 08852, USA
1.Zhang L., Reilly J. P. Extracting both peptide sequence and glycan structural information by 157 nm photodissociation of N-linked glycopeptides. Journal of Proteome Research.2009; 8:734-742
2.Jung K., Cho W., Regnier F. E. Glycoproteomics of plasma based on narrow selectivity lectin affinity chromatography. Journal of Proteome Research.2009; 8: 643–650
3.Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H. Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. Journal of Proteome Research.2009; 8:651-661
4.Li Y., Sokoll L. J., Rush J., Meany D., Zou N., Chan D. W., Zhang H. Targeted detection of prostate cancer proteins in serum using heavy peptide standards and MALDI-TOF/TOF. Proteomics-Clinical. Application. 2009;3:597-608
5.Darula Z., Medzihradszky K. F. Affinity enrichment and characterization of mucin core-1 type glycopeptides from bovine serum. Molecular Cellular Proteomics.2009;8:2515-2526
6.Jung K., Cho W., Regnier F. E. Glycoproteomics of plasma based on narrow selectivity lectin affinity chromatography. Journal of Proteome Research.2009. 8, 643–650
7.Taniguchi N. Toward cancer biomarker discovery using the glycomics approach. Proteomics;2008; 8:3205-3208
8.HILIC based enrichment protocols for characterization of serum glycoproteins by mass spectrometry. Journal of Proteomics. 2008; 71:304–317
9.Polanski M., Anderson N. L. A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights.2007; 1:1-48
10.Comunale MA, Lowman M, Long RE, Krakover J, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res.2006;5:308–15.
11.An HJ, Miyamoto S, Lancaster KS, Kirmiz C, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006;5:1626–35.
12.Dai Z, Liu YK, Cui JF, Shen HL, et al. Identification and analysis of altered alpha1,6-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics. 2006;6:5857–67.
13.Zhao J, Simeone DM, Heidt D, Anderson MA, et al. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res. 2006;5:1792–802.
14.Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D. T., Loo J. A. Identification ofN-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry. Journal of Proteome Research.2006; 5:1493-1503
15.Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D. T., Loo J. A. (2006) Identification ofN-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry. Journal of Proteome Research.2006; 5:1493-1503
16.Harvey D. J. Proteomic analysis of glycosylation: structural determination of N- and O-linked glycans by mass spectrometry. Expert. Rev. Proteomics.2005; 2: 87-101
17.Pan S., Zhang H., Rush J., Eng J., Zhang N., Patterson D., Comb M. J., Aebersold R. H. High-throughput proteome-screening approach for biomarker detection. Molecular. Cellular Proteomics.2005; 4, 182-190
18.Kobata A., Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunology & Cell Biology.2005;83:429-439